NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03425279,CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma,https://clinicaltrials.gov/study/NCT03425279,,ACTIVE_NOT_RECRUITING,The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.,NO,Undifferentiated Pleomorphic Sarcoma|Myxofibrosarcoma,BIOLOGICAL: CAB-AXL-ADC|BIOLOGICAL: PD-1 inhibitor,"Phase 1: Safety Profile, Assess dose limiting toxicity as defined in the protocol, Up to 24 months|Phase 1: Safety Profile, Assess maximum tolerated dose as defined in the protocol, Up to 24 months|Phase 1 and 2: Safety Profile, Frequency and severity of AEs and/or SAEs, and changes from baseline in laboratory parameters and vital signs, Up to 24 months|Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1, Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1, Up to 24 months","Phase 1: Pharmacokinetics, Plasma concentrations of ADC, total antibody and MMAE, Up to 24 months|Phase 1: Pharmacokinetics, Peak Plasma Concentration (Cmax), Up to 24 months|Phase 1: Pharmacokinetics, Area under the plasma concentration versus time curve (AUC), Up to 24 months|Phase 1: Overall response rate (ORR), Proportion of patients who achieve a confirmed CR or PR, Up to 24 months|Phase 1: Immunogenicity, The number and percentage of patients who develop detectable anti-drug antibodies (ADAs), Up to 24 months|Phase 1 and 2: Duration of response (DOR), Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first, Up to 24 months|Phase 1 and 2: Progression-free survival (PFS), Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first, Up to 24 months|Phase 1 and 2: Best overall response (BOR), All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy, Up to 24 months|Phase 1 and 2: Disease control rate (DCR), Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) â‰¥ 12 weeks, Up to 24 months|Phase 1 and 2: Time to response (TTR), Time from the first dose of investigational product until the first documentation of OR, Up to 24 months|Phase 1 and 2: Overall survival (OS), Time from the first dose of BA3011 treatment until death due to any cause, Up to 24 months|Phase 1 and 2: Tumor size, Percent change from baseline in tumor size, Up to 24 months",,"BioAtla, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,300,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BA3011-001,2018-02-15,2025-01,2025-01,2018-02-07,,2025-03-25,"The University of Arizona Cancer Center, Tucson, Arizona, 85724, United States|Children's Hospital Los Angeles, Los Angeles, California, 90027, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Tower Hematology Oncology Medical Group, Los Angeles, California, 90048, United States|Precision NextGen Oncology, Los Angeles, California, 90212, United States|UCSF Medical Center - Cancer Immunotherapy Clinic (CIC), San Francisco, California, 94158, United States|University of Colorado, Aurora, Colorado, 80045, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, 80218, United States|Children's Research Institute, Washington, D.C., District of Columbia, 20010, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Northwestern University, Chicago, Illinois, 60611, United States|Norton Cancer Institute, Louisville, Kentucky, 40202, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, 63110, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, 89169, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|Columbia University, New York, New York, 10032, United States|Memorial Sloan Kettering, New York, New York, 10065, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|The Christ Hospital, Cincinnati, Ohio, 45219, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, 44106, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, 19106, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Prince of Wales Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan",
